Who is sponsoring NCT04945616?

NCT04945616 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT04945616?

Interventions in NCT04945616: Aspirin、clopidogrel、placebo or SHR2285, Aspirin、clopidogrel、placebo or SHR2285, Aspirin、ticagrelor、placebo or SHR2285.

What condition does NCT04945616 study?

NCT04945616 studies Thrombosis.

Is NCT04945616 still recruiting?

NCT04945616 is currently completed. Last updated 1 July 2022.

Last reviewed 2022-07-01 · How we verify

NCT04945616

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Evaluate the Safety and Tolerability of Combined Administration of SHR2285 Tablets With Aspirin, Clopidogrel or Ticagrelor in Healthy Subjects

Completed Phase 1 Last updated 1 July 2022

What this trial tests

Phase 1 trial testing Aspirin、clopidogrel、placebo or SHR2285 in Thrombosis in 52 participants. Completed in 15 June 2022.

Timeline

13 July 2021

Primary endpoint
19 October 2021

15 June 2022

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	other
Enrollment	52
Start date	13 July 2021
Primary completion	19 October 2021
Estimated completion	15 June 2022
Sites	1 location across China

Drugs / interventions tested

Aspirin、clopidogrel、placebo or SHR2285 — full drug profile →
Aspirin、clopidogrel、placebo or SHR2285 — full drug profile →
Aspirin、ticagrelor、placebo or SHR2285 — full drug profile →

Conditions studied

Thrombosis — all drugs for Thrombosis →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

Adults 18 to 55, any sex, with Thrombosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a single-center，randomized, doubled-blinded, placebo-controlled, Only for SHR2285 Phase I trial. This study intends to enroll 52 healthy subjects, regardless of gender. The subjects are divided into three groups: A, B, and C, with 16 cases in each of groups A and B, and 20 cases in group C.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Factor XIa Inhibitors as a Novel Anticoagulation Target: Recent Clinical Research Advances.
Xia Y, Hu Y, Tang L. · · 2023 · cited 12× · PMID 37375813 · DOI 10.3390/ph16060866
SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor.
Ma T, Dong Y, Huang L, Yang Y, et al · · 2022 · cited 9× · PMID 36339534 · DOI 10.3389/fphar.2022.1027627
Safety, tolerability, pharmacokinetics and pharmacodynamics of milvexian with aspirin and/or clopidogrel in healthy participants.
Perera V, Abelian G, Luettgen J, Aronson R, et al · · 2024 · cited 1× · PMID 39025971 · DOI 10.1038/s41598-024-67182-8

Verify or expand the search:

Other recruiting trials for Thrombosis

Currently open trials in the same condition.

NCT07137429 — Platelet Volunteers, Longitudinal and Multi-omic Study · recruiting
NCT06676904 — Neonatal Platelet Transfusion Threshold Trial · NA · recruiting
NCT06993740 — Effect of Dexmedetomidine on Microsurgery Reconstruction in Cancer Patient · NA · recruiting
NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery. · active not recruiting
NCT06370273 — Thromboprophylaxis in Lower Limb Immobilisation · Phase 3 · recruiting

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04945616 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 1 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04945616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing